11-(Chloroacetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one → HCID 18599939, 화합물
반응식
Cl[CH2:2][C:3]([N:5]1[C:11]2[CH:12]=[CH:13][CH:14]=[CH:15][C:10]=2[C:9](=[O:16])[NH:8][C:7]2[CH:17]=[CH:18][CH:19]=[N:20][C:6]1=2)=[O:4].[NH:21]1[CH2:25][CH2:24][CH2:23][C@H:22]1[CH2:26][N:27]1[CH2:32][CH2:31][O:30][CH2:29][CH2:28]1.C(OCC)(=O)C.CO>C(O)C>[N:27]1([CH2:26][C@@H:22]2[CH2:23][CH2:24][CH2:25][N:21]2[CH2:2][C:3]([N:5]2[C:11]3[CH:12]=[CH:13][CH:14]=[CH:15][C:10]=3[C:9](=[O:16])[NH:8][C:7]3[CH:17]=[CH:18][CH:19]=[N:20][C:6]2=3)=[O:4])[CH2:32][CH2:31][O:30][CH2:29][CH2:28]1참가 물질
5
실험 절차
The title compound is prepared analogously to Example 31 from 11-(chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one and (S)-4-[(2-pyrrolidinyl)methyl]morpholine to give colorless crystals, mp. 202-203° C. (ethyl acetate/methanol 1:1 v/v); [α]D20 =-2.93° C. (ethanol).